Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells

被引:45
作者
Bleumer, Ivar [1 ]
Tiemessen, Dorien M. [1 ]
Oosterwijk-Wakka, Jeannette C. [1 ]
Voller, Maureen C. W. [1 ]
De Weijer, Kim [1 ]
Mulders, Peter F. A. [1 ]
Oosterwijk, Egbert [1 ]
机构
[1] Univ Nijmegen, Med Ctr, Nijmegen, Netherlands
关键词
kidney tumor; cancer; vaccines; CA9; G250; peptide; renal cell carcinoma; dendritic cells; immunotherapy; cytokines;
D O I
10.1097/01.cji.0000211318.22902.ec
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Carbonic anhydrase-IXG250/MN (CA9) is a renal cell carcinoma (RCC)-associated antigen ubiquitously expressed in the clear-cell subtype of RCC. Two CA9-derived peptides have been identified defining a cytotoxic T-lymphocyte epitope and human leukocyte antigen (HLA)-DR epitope, able to induce T-cell responses in vitro. A phase I clinical trial was performed with CA9-peptide-loaded dendritic cells (DCs) in patients with progressive, cytokine-reftactory metastatic RCC to assess the safety, toxicity, and induction of CA9-specific immunity. Patients with objective progressive metastatic RCC received 5 vaccinations of mature DCs pulsed with the CA9-derived peptides and keyhole limpet hemocyanine (KLH). Peripheral blood was collected at regular intervals, delayed-type hypersensitivity (DTH) was tested at baseline and after the last vaccination, and skin biopsies of positive DTH sites were collected for immunomonitoring purposes. Patients were also monitored for clinical responses. No significant toxicity was observed. All patients developed Immoral responses against KLH, and demonstrated DTH conversion. Evaluation of biopsy material suggested an increased influx of T-helper cells. In none of the immunomonitoring assays was evidence for the induction of CA9-peptide-specific immunity observed. No clinical responses were observed. The vaccination of DCs pulsed with KLH and 2 CA9-derived peptides was well tolerated. The lack of induction of CA9-peptide-specific immune responses indicates that this particular vaccine regimen is poor in inducing CA9-peptide-specific immune responses.
引用
收藏
页码:116 / 122
页数:7
相关论文
共 18 条
[1]   Immunotherapy for renal cell carcinoma [J].
Bleumer, I ;
Oosterwijk, E ;
De Mulder, P ;
Mulders, PFA .
EUROPEAN UROLOGY, 2003, 44 (01) :65-75
[2]   Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome [J].
de Vries, IJM ;
Bernsen, MR ;
Lesterhuis, WJ ;
Scharenborg, NM ;
Strijk, SP ;
Gerritsen, MJP ;
Ruiter, DJ ;
Figdor, CG ;
Punt, CJA ;
Adema, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5779-5787
[3]  
ESCUDIER B, 2005, ASCO ANN M
[4]   Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma [J].
Gleave, ME ;
Elhilali, M ;
Fradet, Y ;
Davis, I ;
Venner, P ;
Saad, F ;
Klotz, LH ;
Moore, MJ ;
Paton, V ;
Bajamonde, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) :1265-1271
[5]  
Grabmaier K, 2000, INT J CANCER, V85, P865, DOI 10.1002/(SICI)1097-0215(20000315)85:6<865::AID-IJC21>3.0.CO
[6]  
2-Q
[7]  
HARRIS DT, 1983, SEMIN ONCOL, V10, P422
[8]  
Hernández JM, 2003, CLIN CANCER RES, V9, P1906
[9]  
Höltl L, 2002, CLIN CANCER RES, V8, P3369
[10]  
MOTZER RJ, 2005, ASCO ANN M